Robert Nelsen

Robert Nelsen

Patrimonio netto: 2 M $ in data 31/05/2026

62 anni
Health Technology
Commercial Services
Finance

Profilo

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners.
Some of his notable early-stage investments include Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), June Therapeutics (JUNO – acquired by Celgene), Beam Therapeutics (BEAM), Karuna Therapeutics (KRTX), Altos Labs, EQRx (EQRX), National Resilience, Prime Medicine, Lyell Immunopharma (LYEL), Array BioPharma (ARRY – acquired by Pfizer), Hua Medicine (2552:HK), Vir Biotechnology (VIR), Insitro, Agios Pharmaceuticals (AGIO), Sage Therapeutics (SAGE), GRAIL (acquired by Illumina), Gossamer Bio (GOSS), Ikaria (acquired by Mallinckrodt), Kythera Biopharmaceuticals (KYTH – acquired by Allergan), Receptos (RCPT – acquired by Celgene), Aviron (AVIR – acquired by MedImmune), Denali Therapeutics (DNLI), Syros Pharmaceuticals (SYRS), Sana Biotechnology (SANA), Verve Therapeutics (VERV), Brii Biosciences (2137:HK), Bluebird Bio (BLUE), R2 Technology (acquired by Hologic), Caliper Life Sciences (CALP – acquired by PerkinElmer), Trubion Pharmaceuticals (TRBN – acquired by Emergent Biosolutions), Adolor (ADLR – acquired by Cubist Pharmaceuticals), deCODE Genetics (DCGN – acquired by Amgen), Editas (EDIT), 10x Genomics, Semma Therapeutics (acquired by Vertex Pharmaceuticals), Element, and IDUN Pharmaceuticals (acquired by Pfizer).
Mr. Nelsen is a director of VIR, SANA, LYEL, National Resilience, Insitro, Prime Medicine, Nutcracker Therapeutics, Neumora Therapeutics, Brii Biosciences, and serves as Chairman of Hua Medicine, among others.
He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute of Systems Biology, and was a director of the National Venture Capital association.
Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S.
from the University of Puget Sound with majors in Economics and Biology.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValutazioneData di valutazione
31/03/2025 60.615 ( 0,06% ) 2 M $ 31/05/2026
05/06/2026 100.142 ( 0,06% ) 355 504 $ 31/05/2026
31/12/2024 150.000 ( 0,01% ) 50 336 $ 31/05/2026
04/06/2026 13.853 ( 0,01% ) 45 715 $ 31/05/2026

Posizioni attive di Robert Nelsen

SocietàPosizioneInizio
HUA MEDICINE (SHANGHAI) LTD. Presidente 23/04/2010
PRIME MEDICINE, INC. Direttore/Membro del Consiglio 01/09/2020
SANA BIOTECHNOLOGY, INC. Fondatore 13/07/2018
Fondatore 28/06/2010
Direttore/Membro del Consiglio 01/01/2022
Presidente -
Hua Medicine Technology (Hong Kong) Ltd.
Direttore/Membro del Consiglio 01/08/2010
Direttore/Membro del Consiglio -
Direttore/Membro del Consiglio -
░░░░ ░░░░░░░ ░░░░░░░░ ░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░ ░░░░░ ░░░░░ ░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░ ░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░

Precedenti posizioni note di Robert Nelsen

SocietàPosizioneFine
░░░ ░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░░░░
Vedi nel dettaglio l'esperienza di Robert Nelsen

Formazione di Robert Nelsen

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

64

Relazioni di 1° grado

80

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private80

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Finance

Finance

Process Industries

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Energy Minerals

Health Technology

Health Technology

Health Technology

Producer Manufacturing

Health Technology

Miscellaneous

Consumer Services

Technology Services

Consumer Services

Finance

Health Technology

Commercial Services

Health Technology

Commercial Services

Commercial Services

Commercial Services

Finance

Commercial Services

Health Technology

Finance

Commercial Services

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Technology Services

Health Technology

Hua Medicine Technology (Hong Kong) Ltd.

Health Technology

Health Technology

Health Technology

Commercial Services

Finance

Health Technology

Health Services

Health Technology

Health Technology

Finance

Commercial Services

Brii Biosciences (Beijing) Co. Ltd.

Brii Biosciences (Hong Kong) Co. Ltd.

Health Technology

Finance

Health Technology

Health Technology

Technology Services

Health Technology

Technology Services

  1. Mercati
  2. Insiders
  3. Robert Nelsen
- 40%: I migliori strumenti riservati agli abbonati per individuare le opportunità di investimento di domani.
g
:
:
ENTRA ORA